Methionine and vitamin B-complex ameliorate antitubercular drugs-induced toxicity in exposed patients

Pharmacology Research and Perspectives

Volumn 5, Issue 5, 2017, Pages

  Amagon, Kennedy I ^a,b   Awodele, Olufunsho ^a   Akindele, Abidemi J ^a  

^a UNIVERSITY OF LAGOS   (Nigeria)

^b UNIVERSITY OF JOS   (Nigeria)

Author keywords

Antioxidants; biomarkers; drug toxicity; methionine; modulation; tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALKALINE PHOSPHATASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; GLUTATHIONE; MALONALDEHYDE; METHIONINE; SUPEROXIDE DISMUTASE; TUBERCULOSTATIC AGENT; UREA; VITAMIN B GROUP; VITAMIN B COMPLEX;

ABDOMINAL PAIN; ADULT; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DIZZINESS; DRUG TOXICITY; ERYTHROCYTE COUNT; FATIGUE; FEMALE; FEVER; GENERAL HOSPITAL; HEADACHE; HEMATOCRIT; HUMAN; LIVER TOXICITY; LOSS OF APPETITE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA AND VOMITING; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RISK FACTOR; SMOKING; TREATMENT OUTCOME; TUBERCULOSIS; WEAKNESS; ADVERSE DRUG REACTION; BLOOD; COMBINATION DRUG THERAPY; METABOLISM; NIGERIA; YOUNG ADULT;

ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANTITUBERCULAR AGENTS; ASPARTATE AMINOTRANSFERASES; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; METHIONINE; MIDDLE AGED; NIGERIA; PROSPECTIVE STUDIES; TUBERCULOSIS; VITAMIN B COMPLEX; YOUNG ADULT;

EID: 85030216565     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.360     Document Type: Article

References (49)

1. Alomar MJ (2014). Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J 22: 83–94.
2. Alvarado AM, Navarro SA (2016). Complex B vitamins: physiology and therapeutic effect on pain. Am J Pharm Sci 4: 20–27.
3. Amilo GI, Meludu SC, Ele PU, Ezechukwu C, Onyenekwe C, Chukwu MI (2013). Haematologic indices in pulmonary tuberculosis with or without HV Co-infection in South Eastern Nigeria. Adv Life Sci Tech 11: 1–7.
4. Anisimova SI, Donchenko GV, Parkhomenko YM, Kovalenko VM (2013). Mechanism of hepatoprotective action of methionine and composition “Metovitan” against a background of antituberculosis drugs administration to rats. Ukr Biochem J 85: 59–67.
5. Anstee QM, Day CP (2012). S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol 57: 1097–1109.
6. Awodele O, Agbaje EO, Adesina EA, Akintonwa A (2011). Hepatoprotective role of neutrosecR on hepatic damage induced by combination of zidovudine and combined anti-tuberculous agents in rats. Tokai J Exp Clin Med 36: 31–36.
7. Bharti U, Kumar NR, Kaur J (2017). Protective effect of bee propolis against anti-tuberculosis drugs (rifampicin and isoniazid)-induced haematological toxicity in Sprague Dawley rats. Asian J Pharm Clin Res 10: 188–190.
8. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. (2003). Treatment of tuberculosis. Am J Respir Crit Care Med 167: 603–662.
9. Burda AM, Sigg T, Haque D, Bardsley CH (2007). Inadequate pyridoxine stock and its effect on patient outcome. Am J Ther 14: 262–264.
10. Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Velez-Segovia E, Soria-Montoya A, Nuñez-Garbin A, et al. (2011). Factors associated with anti-tuberculosis medication adverse effects: a case-control study in lima, Peru. PLoS ONE 6: e27610.
11. Cooper GM, Hausman RE (2015). The Cell: a Molecular Approach. 7th ed. Sinauer Associates, Sunderland (MA).
12. Devarbhavi H, Dierkhising R, Kremers WK (2010). Antituberculosis therapy drug-induced liver injury and acute liver failure. Hepatol 52: 798–799.
13. Essop AR, Posen JA, Hodkinson JH, Segal I (1984). Tuberculosis hepatitis: a clinical review of 96 cases. QJ Med 53: 465–477.
14. Farazi A, Sofian M, Jabbariasl M, Keshavarz S (2014). Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients. Tuberc Res Treat 2014: 412893.
15. Ghosh K, Indra N, Jagadeesan G (2017). The ameliorating effect of Centella asiatica ethanolic extract on albino rats treated with isoniazid. J Basic Clin Physiol Pharmacol 28: 67–77.
16. Hamza RZ, Al-Harbi MS (2015). Amelioration of paracetamol hepatotoxicity and oxidative stress on mice liver with silymarin and Nigella sativa extract supplements. Asian Pac J Trop Biomed 5: 521–531.
17. 6: a molecule for human health? Mol 15: 442–459.
18. Huang SC, Benz EJ (2001). Posttranscriptional factors influencing the hemoglobin content of the red cell. Pp. 146–173 in M. H. Steinberg, D. Higgs and R. L. Nagel, (eds). Disorders of hemoglobin: genetics, pathophysiology, and clinical management. Cambridge University Press Cambridge, United Kingdom.
19. Huiri A, Xueqiong W, Zhongyuan W, Jing X, Shaohua Z, Kun W (2017). The clinical characteristics of anti-tuberculosis drug induced liver injury in 2457 hospitalized patients with tuberculosis in China. Afr J Pharm Pharmacol 7: 710–714.
20. Hungund BR, Sangolli SS, Bannur HB (2012). Blood and bone marrow findings in tuberculosis in adults-A cross sectional study. AlAmeen J Med Sci 5: 362–366.
21. Isa SE, Ebonyi AO, Shehu NY, Idoko P, Anejo-Okopi JA, Simji G, et al. (2016). Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria. Int J Mycobacteriol 5: 21–26.
22. Jeong I, Park JS, Co YJ, Yoon H, Song J, Lee CT, et al. (2015). Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. J Korean Med Sci 30: 167–172.
23. Kaona FA, Tuba M, Siziya S, Sikaona L (2004). An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health 4: 68.
24. Kassa E, Enawgaw B, Gelaw A, Gelaw B (2016). Effect of anti-tuberculosis drugs on haematological profiles of tuberculosis patients attending at University of Gondar Hospital Northwest Ethiopia. BMC Haematol 16: 1–11.
25. Kaswala DH (2013). Drug rash with eosinophilia and systemic symptoms syndrome due to anti-TB medication. J Family Med Prim Care 2: 83–85.
26. Koju D, Rao BS, Shrestha B, Shakya R, Makaju R (2005). Occurrence of side effects from anti-tuberculosis drugs in urban Nepalese population under DOTS treatment. Kathmandu University J Sci Eng Technol 1: 1–8.
27. Kwon SH, Kim JH, Yang JO, Lee EY, Hong SY (2004). Ethambutol-induced acute renal failure. Nephrol Dial Transplant 14: 1335–1336.Erratum in: Nephrology Dialysis Transplantation 2004;19:2160.
28. Liu X, Zhao M, Mi J, Chen H, Sheng L, Li Y (2017). Protective effect of bicyclol on anti-tuberculosis drug induced liver injury in rats. Mol 22: 524.
29. Manika K, Tasiopoulou K, Vlogiaris L, Lada M, Papaemmanouil S, Zarogoulidis K, et al. (2013). Rifampicin-associated acute renal failure and hemolysis: a rather uncommon but severe complication. Ren Fail 35: 1179–1181.
30. Mohajan HK (2015). Tuberculosis is a fatal disease among some developing countries of the world. Am J Infect Dis Microbiol 3: 18–31.
31. Niedzwiecki MM, Hall MN, Liu X, Oka J, Harper KN, Slavkovich V, et al. (2013). Blood glutathione redox status and global methylation of peripheral blood mononuclear cell DNA in Bangladeshi adults. Epigenetics 8: 730–738.
32. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S (2008). The current state of serum biomarkers of hepatotoxicity. Toxicol 245: 194–205.
33. Pretorius RW, Gataric G, Swedlund SK, Miller JR (2013). Reducing the risk of adverse drug events in older adults. Am Fam Phys 87: 331–336.
34. Rademaker M (2001). Do women have more adverse drug reactions? Am J Clin Dermatol 2: 349–351.
35. Ramaiah SK (2007). A toxicologist's guide to the diagnostic interpretation of hepatic biochemical parameters. Food Chem Toxicol 45: 1551–1557.
36. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E (2008). The antioxidant properties of serum albumin. FEBS Lett 582: 1783–1787.
37. Schubert C, Bates WD, Moosa MR (2010). Acute tubulointerstitial nephritis related to antituberculous drug therapy. Clin Nephrol 14: 413–419.
38. Seetharam B, Li N (2000). Transcobalamin II and its cell surface receptor. Vitam Horm 59: 337–366.
39. Shabana MB, Ibrahim HM, Khadre SEM, Elemam MG (2012). Influence of rifampicin and tetracycline administration on some biochemical and histological parameters in albino rats. J Basic Appl Zool 65: 299–308.
40. Shingdang J, Bot Y, Ojo O, Edeh O, Essien C, Bwende E, et al. (2016). Serum Albumin/Globulin ratio in Tuberculosis and HIV Patients any Relationship? Mycobact Dis 6: 199.
41. Singh D, William C, Cho WC, Upadhyay G (2016). Drug-Induced liver toxicity and prevention by herbal antioxidants: an overview. Front Physiol 6: 1–18.
42. Stine JG, Chalasani N (2015). Chronic liver injury induced by drugs: a systematic review. Liver Int 35: 2343–2353.
43. Teschke R, Danan G (2016). Review article: diagnosis and management of drug-induced liver injury (DILI) in patients with pre-existing liver disease. Drug Saf 39: 729–744.
44. Teschke R, Danan G (2017). Drug-induced liver injury: is chronic liver disease a risk factor and a clinical issue? Expert Opin Drug Metab Toxicol 13: 4.
45. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R (2008). Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 23: 192–202.
46. Trzeciak-Ryczek A, Tokarz-Deptuła B, Deptuła W (2013). Platelets-an important element of the immune system. Pol J Vet Sci 16: 407–413.
47. Yanardag H, Caner M, Gunes Y, Uygun S (2005). Acute hemolysis and oligoanuric acute renal failure caused by interrupted. Internet J Nephrol 2: 1–3.
48. Yilmaz HR, Uz E, Gökalp O, Ozçelik N, Ciçek E, Ozer MK (2008). Protective role of caffeic acid phenethyl ester and erdosteine on activities of purine-catabolizing enzymes and level of nitric oxide in red blood cells of isoniazid-administered rats. Toxicol Ind Health 24: 519–524.
49. Zhai Q, Lu SR, Lin Y, Yang QL, Yu B (2008). Oxidative stress potentiated by diallylsulfide, a selective CYP2E1 inhibitor, in isoniazid toxic effect on rat primary hepatocytes. Toxicol Lett 183: 95–98.